Actively Recruiting

All Genders
ID07328152

Combination of Data From European Cohorts as Part of the European MORPHEUS Project - MC-MORPHEUS

Led by University Hospital, Brest · Updated on 2026-01-09

20000

Participants Needed

1

Research Sites

287 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The MORPHEUS project is an international research program involving eight European countries, coordinated by France, that aims to improve long-term treatment for unprovoked venous thromboembolic disease (VTED). This research combines clinical, biological, morphological, and socio-anthropological data to create a risk prediction tool to support shared medical decision-making. The MC-MORPHEUS phase focuses on identifying key biomarkers predictive of risks like thromboembolic recurrence, bleeding, and mortality. MC-MORPHEUS collects and merges data from 14 European cohorts into a single database, integrating clinical, biological, and morphological information from patients with venous thromboembolism who have been followed for months or years. This combined dataset will enhance the identification of important biomarkers, which will be used to develop and validate a time-dependent, multi-level risk prediction tool in future studies. Participants in these cohorts have been monitored over long periods, and the study involves processing and analyzing this merged data from late 2024 through 2025. The research will assess consistency between merged and original cohort data and evaluate long-term risks of thromboembolic recurrence, bleeding, and death over 20 years. This observational study does not involve direct interventions but focuses on data analysis and tool development to improve VTED treatment.

CONDITIONS

Brief Title

CoMbination of Data From European Cohorts as Part of the European MORPHEUS Project [HORIZON-HLTH-2022-11-01] - "MC-MORPHEUS".

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Cohorts led by members of the European MORPHEUS project consortium
Not Eligible

You will not qualify if you...

  • Lack of consent in cohorts

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Long-term Monitoring

Duration - Up to 20 years

Participants from European cohorts with venous thromboembolic disease are observed over several months and years to identify clinical, biological, and morphological biomarkers for risk prediction.

Trial Site Locations

Total: 1 location

1

Chu Brest

Brest, France, 29609

Actively Recruiting

Loading map...

Research Team

F

Francis COUTURAUD

C

Cécile TROMEUR

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Multicenter, Randomized, Open-Label, Blinded Endpoint Eval...

Venous Thromboembolism

Actively Recruiting

1 location

An Open-label Pilot Study to Evaluate Medication Satisfactio...

Venous Thromboembolism

Actively Recruiting

1 location

Long-Term Clinical Evaluation of Aspiration Thrombectomy Usi...

Arterial Thromboembolism

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here